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José R. Santos,1,2 Josep M. Llibre,1,2 Pere Domingo,2,3 Arkaitz Imaz,2,4 Elena Ferrer,5 Daniel Podzamczer,5
Isabel Bravo,1 Esteban Ribera,2,4 Sebastià Videla,1 and Bonaventura Clotet1,6
Abstract
The effectiveness of etravirine has not been thoroughly investigated in routine clinical practice, where adherence
rates and the heterogeneous nature of patients differ from the clinical trial setting. We evaluated the effectiveness of
rescue regimens containing etravirine and the factors associated with treatment response. Multicenter retrospective
cohort of all consecutive patients was recruited in a routine clinical practice setting. Patients were taking rescue
regimens containing etravirine plus an optimized background regimen. The primary endpoint was the percentage
of patients with HIV-1 RNA <50 copies/ml at week 48. The secondary endpoints were those factors associated
with treatment response to etravirine. Endpoints were evaluated using univariate and multivariate analysis. A
total of 122 patients were included with a median viral load of 11,938 (1055–55,500) copies/ml at baseline. The
most frequent drugs in the backbone were darunavir/ritonavir in 98 (80.3%) patients and raltegravir in 76 (62.3%).
In the full dataset analysis, 73% (89/122; 95% CI, 64–81%) of patients responded to treatment at week 48; in the on-
treatment analysis, 82% (89/109; 95% CI, 71–87%) responded. The factors associated with treatment failure to
etravirine [HR (95% CI)] were baseline CD4þ T cell count <200 cells/mm3 [2.45 (1.17–5.16)] and use of raltegravir
[0.47 (0.22–0.99)] and darunavir [0.45 (0.21–0.98)] as backbone drugs. Skin rash was the only adverse event directly
related to etravirine and led to withdrawal in three patients (2.5%). In routine clinical practice, rescue ETR-
containing regimens are well tolerated and achieve rates of virological suppression higher than those observed in
its pivotal clinical trials, especially when combined with darunavir and raltegravir.
Introduction
The availability of new drugs, in both existing or novelantiretroviral classes, with expanded activity against
triple-class resistant HIV-1 makes it possible to achieve sus-
tained virologic suppression in multitreated patients in
routine clinical practice. New agents have demonstrated su-
periority in all efficacy parameters in their pivotal salvage
trials.1–6 The combination of these drugs allows us to con-
struct regimens with at least two—and preferably three—
fully active drugs, even in very treatment-experienced indi-
viduals.7,8 However, with the exception of the DUET-1 and
DUET-2 studies,2,3 no trials have compared the efficacy of the
different combinations of these drugs to date. In the DUET
studies, darunavir was combined with etravirine (ETR) in all
patients, and neither raltegravir nor maraviroc was available.
The efficacy of etravirine at 24 weeks rose to 66% in patients
from DUET-1 and 80% from DUET-2. In both trials, patients
achieved sustained virological suppression with regimens
containing three or more active agents.2,3 The safety and ef-
ficacy of ETR in combination with the remaining new anti-
retrovirals have not been evaluated outside the strictly
controlled conditions of a clinical trial, although preliminary
reports on the combination of these new drugs have shown
promising results.9–12
We evaluated the effectiveness of rescue regimens contain-
ing ETR combined with all the available active agents in routine
clinical practice. We also analyzed the relationship between the
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number of additional active drugs in the optimized regimen
and other factors associated with the response to ETR.
Materials and Methods
We conducted a multicenter retrospective study of HIV-1-
infected patients aged at least 18 years who started an anti-
retroviral rescue regimen containing ETR between June 2003
and November 2009. Patients were recruited at the HIV units of
four acute-care university hospitals in Barcelona, Spain.
Patients with virological failure (at least two successive HIV-1
plasma RNA measurements>50 copies/ml) who had started a
rescue therapy were selected through a systematic search of the
electronic files at each center. All patients were treatment ex-
perienced and had resistance to three antiviral classes: nucle-
oside reverse transcriptase inhibitors (NRTIs), nonnucleoside
reverse transcriptase inhibitors (NNRTIs), and protease inhib-
itors (PIs). Clinicians selected the backbone regimen according
to genotyping results and treatment history, and ETR was
started at doses of 200 mg orally twice daily. Demographic
characteristics, treatment history, historical and current HIV-1
genotypic resistance test results, and tropism (Trofile; Mono-
gram Biosciences, Inc., CA) were recorded. HIV-1 RNA (Roche
HIV-1 RNA Ultrasensitive PCR assay; Hoffmann-La Roche,
Basel, Switzerland) measurements and CD4þ T cell counts
were recorded at baseline and every 12 weeks thereafter.
The primary endpoint was the proportion of patients with an
HIV-1 viral load <50 copies/ml at 48 weeks. Secondary end-
points included the relationship between treatment response
and the number of active antiretrovirals at baseline, CDC stage,
CD4þ T cell count and viral load 100,000 copies/ml at base-
line, number of previous lines of treatment, number of previous
antiretrovirals, number of NNRTIs/NRTIs/PIs, previous fail-
ure or interruption with efavirenz or nevirapine, adverse events
leading to discontinuation of therapy, and changes in CD4þ T
cell counts. Treatment failure was defined as a confirmed viral
load >50 copies/ml before week 48 or early discontinuation of
ETR for any reason. The number of active drugs was calculated
using the HIV Drug Resistance Database, Stanford (version
6.0.8). We assigned 1, 0.5, or 0 points to drugs with scores of
<15, 15–59, and 60 points, respectively. Enfuvirtide and ral-
tegravir were considered active in those patients using the
drugs for the first time. Maraviroc was considered active in
those patients who had CCR5 tropism.
The primary endpoint was measured in all patients who
started treatment (full dataset). The last observation carried
forward was used if no information was available at week 48.
Quantitative variables are expressed as mean (SD) or median
and interquartile range, and qualitative variables as percent-
ages. Normally distributed variables were compared using the
t test; nonnormally distributed variables were compared using
the Wilcoxon rank sum test. The relationship between treat-
ment response, clinical characteristics, and number of active
drugs at baseline was assessed using univariate and multi-
variate (Cox regression) analysis. The hazard ratio and its 95%
confidence interval (95% CI) were also calculated. All statistical
analyses were performed using SPSS version 15.0 for Windows
(SPSS, Chicago, IL). Statistical significance was set at p< 0.05.
Results
A total of 122 patients with virological failure started a
rescue regimen containing ETR. Patients had received a me-
dian of 8 (4–10) antiretroviral regimens over a mean of 11.9
(4.2) years and had a median HIV-1 RNA of 11,938 (1055–
55,500) copies/ml. When rescue therapy was started, 82
(67.2%) and 67 (54.9%) patients had experienced failure or
interruption of previous regimens with nevirapine or efavir-
enz, respectively. Darunavir and raltegravir were the most
frequent drugs in the backbone regimens, and were taken
by 98 (80.3%) and 76 (62.3%) patients, respectively. Only 11
(9%) patients took maraviroc, 8 (6.6%) lopinavir/ritonavir,
and 5 (4.1%) atazanavir/ritonavir. Baseline characteristics are
shown in Table 1.
Of the 122 patients included in the study, 89 (73%, 95% CI:
64–81%) achieved virological suppression in the full dataset
analysis and 33 (27%, 95% CI: 19–35%) experienced treatment
failure at 48 weeks. Of these, 17 (51.5%) had confirmed viro-
logical failure, 11 (33.3%) were lost to follow-up, 3 (9.1%) ex-
perienced a toxicity-limiting adverse event with ETR, and 2
(6%) stopped treatment. These last two patients had achieved
complete viral suppression when they voluntarily decided
to discontinue. As a result, the proportion of patients who
achieved treatment response at week 48 in the on-treatment
analysis was 89/109 (82 %).
Factors found to predict treatment failure at 48 weeks in
the univariate analysis were baseline CD4þ T cell count <200
cells/mm3 [(HR¼ 2.148; 95% CI, 1.029–4.483); p¼ 0.042], use
of raltegravir [(HR¼ 0.452; 95% CI, 0.225–0.908); p¼ 0.026]
and darunavir [(HR¼ 0.380; 95% CI, 0.184–0.783); p¼ 0.009]
as backbone drugs, and time on antiretroviral treatment (risk
per year) [(HR¼ 0.921; 95% CI, 0.851–0.998); p¼ 0.043]. In the
multivariate analysis, only the baseline CD4þ T cell count
<200 cells/mm3 [(HR¼ 2.458; 95% CI, 1.170–5.166); p¼ 0.018]
and use of raltegravir [(HR¼ 0.459; 95% CI, 0.214–0.985);
p¼ 0.046] and darunavir [(HR¼ 0.474; 95% CI:0.226–0.994),
p¼ 0.048] were identified as predictors of treatment response.
The factors not identified as predictors of treatment response
in the univariate analysis were a viral load >100,000 copies/
ml (HR¼ 1.056, 95% CI, 0.406–2.751), overall time since HIV-1
diagnosis, prior interruption or failure on regimens con-
taining nevirapine and efavirenz, and number of previous
antiretroviral regimens, number of fully active drugs (3
at baseline), and number of previous PIs/NRTIs/NNRTIs
(Table 2).
According to the Stanford HIVDB score (version 6.0.8),
ETR was fully active in 56/122 (45.9%) patients, intermedi-
ate in 49/122 (40.2%), and resistant in 8/122 (6.6%). The
baseline genotyping result was not available in 9/122 (7.4%)
patients.
As for the number of active antiretrovirals in the backbone
regimen, 10 of the 17 patients who experienced virological
failure (58.82%) had 2.5 active drugs and 7/17 (41.17%) had
3.0 active drugs. Of these, two patients who were on mar-
aviroc, four on lopinavir/ritonavir, and two on atazanavir/
ritonavir experienced virological failure despite taking 2.5
active drugs at baseline. In addition, according to their med-
ical records, these six (35.29%) patients had poor adherence,
which could explain their treatment failure, even though they
were taking active drugs at baseline. Unfortunately, the de-
sign of the study and the heterogeneity of the medical records
meant that it was not possible to correctly evaluate adherence
in the remaining patients.
In addition to virological efficacy, rescue regimens con-
taining ETR resulted in a significant overall increase in CD4þ






















































T cell count during follow-up from 274 (213) cells/mm3 at
baseline to 417 (231) cells/mm3 at week 48 ( p< 0.0001).
There were no unexpected adverse events. Sixteen (13.11%)
patients presented side effects associated with their anti-
retroviral treatment. Only three (2.5%) presented adverse
events leading to discontinuation of therapy and the re-
maining 13 (10.65%) maintained their ETR-based regimens.
Rash was the most frequent adverse event and was observed
in eight (6.5%) patients, of whom only three were women
( p¼ 0.359) and six were also using DRV in the backbone.
Three of these eight patients presented a moderate diffuse
rash13 and discontinued ETR (two of them had started dar-
unavir and ETR simultaneously at baseline), four had mild
and transient ETR-related rash, and one experienced a con-
firmed darunavir-related rash after week 24 leading to
discontinuation of darunavir, while ETR was maintained.
NRTI-associated adverse events were reported in six patients
(worsening of neuropathy in three, dizziness caused by em-
tricitabine in one, and anemia caused by zidovudine in two).
Diarrhea due to boosted PI was reported in two patients.
Discussion
Rescue regimens containing ETR plus optimized anti-
retroviral drugs in heavily treatment-experienced individuals
show higher effectiveness rates than those observed in pivotal
ETR trials.2,3,14 In our analysis, 73% of patients achieved a
viral load of <50 copies/ml at 48 weeks in a restrictive full
dataset analysis. This result is higher than the rates observed
in the pooled DUET-1 and 2 trials, where 61% of patients
receiving ETR achieved complete viral suppression.15 This is
contrary to what normally happens in treatment-naive pa-
tients, in whom the excellent response rates seen in clinical
trials are difficult to match in routine clinical practice. This
higher effectiveness of ETR, when prescribed as rescue treat-
ment in clinical practice, is probably due to the availability of
more active agents than were available during the initial
clinical trials.
With the exception of the DUET trials, in which ETR proved
to be more effective than placebo,2,3 few studies have evalu-
ated the efficacy and safety of ETR. ETR with raltegravir and
darunavir (or other boosted PIs) has shown outstanding ef-
ficacy rates and a good safety profile in preliminary clinical
trials and different expanded-access programs, achieving
undetectable viral loads at 48 weeks in as many as 70% and
81% of patients after 48 weeks of treatment.9,10,12,16 Our re-
sults are consistent with these findings, and darunavir and
raltegravir were the most frequently used antiretroviral
agents in the optimized baseline treatments, with high rates of
treatment response and virological suppression. In addition,
viral suppression has also been observed in 92% of patients in
a setting with more limited therapeutic options, namely, a PI
and NRTI-sparing regimen containing ETR plus maraviroc
and raltegravir.11 In our series, the number of patients taking
maraviroc or other boosted PIs (not darunavir) plus ETR was
too low for conclusions to be drawn about efficacy.
The pooled 48-week results from the DUET studies showed
that baseline HIV-1 RNA and CD4þ T cell count, adherence,
number of active agents in the background regimen, and use
of enfuvirtide were predictors of virological response with
ETR in rescue regimens.15 We also found a relationship be-
tween baseline CD4þ T cell count <200 cells/mm3 and
treatment response at week 48, which is consistent with
the fact that advanced stages of HIV infection are associated
with poorer treatment response rates. The DUET trials re-
vealed a significantly greater response in the ETR group than
in the placebo group, irrespective of the number of active
Table 1. Baseline Characteristics of HIV-1-Infected
Patients Taking Rescue Regimens Containing
Etravirine Plus an Optimized
Antiretroviral Regimen
a
Baseline characteristic N¼ 122
Maleb 97 (79.5)







Time since HIV diagnosis (years)d 15.5 (12.2–18.5)
Time on treatment (years)c 11.9 (4.2)
No. of previous antiretroviral
regimensd
7 (4–10)
No. of previous antiretroviral drugsc 10.6 (3.7)
No. of previous NRTIsd 6 (5–7)
No. of previous NNRTIsd 1 (1–2)



















Baseline active drugsd 2.5 (2–3)
1.5 active drugsb 18 (14.9)
2 active drugsb 21 (17.2)
2.5 active drugsb 39 (32)
3 active drugsb 19 (15.6)
3.5 active drugsb 24 (19.7)
CCR5 tropisme (n¼ 36)b
CCR5 15 (41.6)
CXCR4 and D/M 10 (27.7)
Non-reportable 11 (30.5)
CD4þ T cell count (cells/mm3)c 274.4 (213.3)
Viral load (copies/ml)d 11,938 (1055–55,500)
aARV, antiretroviral drugs; HCV, hepatitis C virus; HBV, hepatitis
B virus; NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs,




























































background agents. However, consistent with current HIV-1
treatment guidelines, the use of an increasing number of other
active antiretrovirals with ETR was associated with an in-
creased likelihood of treatment response.7,15,17,18
Similarly, we also found a higher proportion of patients
whose regimen had failed with 2.5 active drugs than with
3 active drugs at baseline, although we were unable to
demonstrate a statistically significant difference ( p¼ 0.802).
The low number of patients taking 2.5 active drugs could
have masked any existing differences, as has been observed in
other salvage studies. In addition, we were unable to find a
relationship between response to treatment and baseline HIV-
1 RNA >100,000 copies/ml, a predictor that is universally
associated with higher rates of treatment failure. In our series,
the number of individuals with baseline viral load >100,000
copies/ml was very low (5/122 patients); therefore, the dif-
ference was not statistically significant. This major drawback
has also been encountered in many current clinical rescue
trials reporting lower median viral loads in patients whose
current antiretroviral treatment has failed in recent years.19,20
These data suggest that the number of active drugs is prob-
ably a stronger predictor of response than a higher viral load
in treatment-experienced patients.
We found no relationship between prior interruption or
failure with NVP or EFV and response to ETR. This is con-
cordant with what was observed in the DUET trials.21
As expected, and consistent with the results of other stud-
ies,2,3,14,15 there was a significant increase in CD4þ T cell count
during follow-up. The only adverse event related to the ad-
ministration of ETR was rash, which occurred in 50% of pa-
tients who experienced possibly or probably drug-related side
effects, although this led to discontinuation in only three pa-
tients (2.5%), while the remaining five patients presented mild
and transient rash that did not require discontinuation. An
association between female gender and ETR-related rash has
been reported,14 although we were not able to observe this
relationship in our study, probably due to the low number of
women included and the low prevalence of rash. No other
unexpected side effects leading to discontinuation of ETR
were observed. However, the rescue regimen was modified
during follow-up, due to the side effects induced by other
families of antiretrovirals: zidovudine-related anemia; pe-
ripheral neuropathy associated with zidovudine, didanosine,
and abacavir; dizziness caused by emtricitabine; and gastro-
intestinal disorders induced by PIs.
In conclusion, in conditions of routine clinical practice,
ETR-containing rescue regimens are generally well tolerated
and achieve rates of virological suppression that exceed those
observed in clinical trials. This is probably due to a higher
number of new active drugs in the regimen. Darunavir and
raltegravir are safe and very effective antiretrovirals when
administered in combination with ETR. Studies that evaluate
Table 2. Factors Predicting Treatment Failure in HIV-1-Infected Patients Taking Rescue Regimens
Containing Etravirine Plus an Optimized Antiretroviral Regimen
a










1.5 active drugs 7 11 1.86 (0.8–4.33) 1.07 (0.24–4.70)
2 active drugs 11 28 1.17 (0.56–2.45) 1.20 (0.29–4.96)
2.5 active drugs 20 58 0.83 (0.41–1.68) 0.47 (0.12–1.81)
3 active drugs 26 71 1.04 (0.45–2.44) 2.07 (0.45–9.48)
Viral load  100,000 copies/ml 5 14 1.05 (0.40–2.75) 1.28 (0.37–4.35)




C 19 35 1.16 (0.52–2.59) 1.10 (0.40–3.01)
Time since HIV diagnosis (years)c 1.0 (0.96–1.04) 0.94 (0.8–1.1)
Time on treatment (years)c 0.92 (0.85–0.99) 1.04 (0.84–1.29)
No. of previous antiretroviral regimens 1.0 (0.92–1.08) 0.99 (0.9–1.09)
No. of previous antiretroviral drugs 0.97 (0.87–1.07) 1.03 (0.53–1.97)
No. of previous NRTIs 0.95 (0.73–1.22) 0.83 (0.39–1.76)
No. of previous NNRTIs 1.4 (0.72–2.7) <0.001 (<0.001–>1000)
No. of previous PIs 0.93 (0.78–1.12) 0.89 (0.43–1.86)
Interruption/failure of previous NNRTIs
NVP 22 60 1.0 (0.46–2.18) 1.99 (0.24–1.51)
EFV 21 46 0.85 (0.39–1.85) 0.88 (0.4–1.92)
ARV at baseline
Darunavir/ritonavir 20 78 0.38 (0.18–0.78) 0.459 (0.214–0.985)
Raltegravir 76 61 0.45 (0.22–0.90) 0.47 (0.22–0.99)
aARV, antiretroviral drugs; CDC, Centers for Disease Control and Prevention; EFV, efavirenz; NRTIs, nucleoside reverse transcriptase
inhibitors; NNRTIs, nonnucleoside reverse transcriptase inhibitors; NVP, nevirapine; PI, protease inhibitor; HR, hazard ratio; CI, confidence
interval.
bBaseline genotyping result was not available in nine patients (n¼ 113).
cRisk per year.






















































the efficacy and safety of ETR in combination with other PIs
and maraviroc are still needed.
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